900000000000526001: REPLACED BY association reference set (foundation metadata concept)

SNOMED CT Concept\SNOMED CT Model Component\Foundation metadata concept (foundation metadata concept)\Reference set\Association type\Historical association reference set (foundation metadata concept)\REPLACED BY association reference set (foundation metadata concept)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module

900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
REPLACED BY association reference set (foundation metadata concept)	Is a	Historical association reference set (foundation metadata concept)	true	Inferred relationship	Some

Members	targetComponentId
Funktionel filtrationspude	Functional filtering bleb (finding)
Drainage of boil of skin NEC	Drainage of boil of skin
Drainage of cyst NEC	Drainage procedure
Drænage af pancreascyste i jejunum, ikke klassificeret andetsteds	Pancreaticocystojejunostomy
drænage af absces i kvindelige perineum	Drainage of perineal abscess (procedure)
Drænage af periuretral absces hos mand	Drainage of periurethral abscess (procedure)
Drainage of organ NOC	Drainage procedure
Drainage of organ NOC NOS	Drainage procedure
Draughtsman NOS	Draughtsman
Drechslera longirostrata	Exserohilum longirostratum
Dressing - action	Application - action
tørret og varmebehandlet faktor IX-fraktion 600 IE, pulver og solvens til injektionsvæske, opløsning, hætteglas	Product containing only coagulation factor IX in parenteral dose form (medicinal product form)
Dried factor IX fraction heated 600iu powder for conventional release solution for injection solution vial	Product containing only coagulation factor IX in parenteral dose form (medicinal product form)
Drilling of organ NOC	Drilling
Drimaren brilliantgul	Textile colours and finishes patch test substance
Driving examination NOS	Driving-related medical examination
Driving examination NOS	Driving-related medical examination
Drop attacks hos middelaldrende kvinde	Drop attack
allergi over for drostanolonpropionat	Allergy to drostanolone (finding)
drotrecogin alfa, aktiveret 5 mg pulver til infusionsvæske, opløsning, hætteglas	Drotrecogin alfa 5 mg powder for solution for injection vial
drotrecogin alfa 20 mg pulver til infusionsvæske, opløsning, hætteglas	Product containing precisely drotrecogin alfa 20 milligram/1 vial powder for conventional release solution for injection (clinical drug)
Drug	Pharmaceutical / biologic product (product)
Drug abuse in remission	Harmful pattern of substance use in remission
Drug addiction notif NOS	Drug addiction notification status
Drug addiction notif NOS	Drug addiction notification
Drug aerosol, 0,01%	Drug aerosol
Drug aerosol, 0,04%	Drug aerosol
Drug aerosol, 0,5%	Drug aerosol
Drug cream, 0,01%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,02%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,025%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,05%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,1%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,25%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,5%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 1%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 2,5%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
afhængighed af rusmiddel	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
afhængighed af psykoaktive stoffer eller lægemidler – uspecificeret om under graviditet eller i puerperiet	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
afhængighed af psykoaktive stoffer eller lægemidler, ikke nærmere specificeret	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
Drug dependence NOS	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
Drug dependence during childbirth, puerperium (& pregnancy)	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
afhængighed af psykoaktive stoffer eller lægemidler under graviditet, fødsel og puerperiet	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
afhængighed af psykoaktive stoffer eller lægemidler under graviditet, fødsel eller i puerperiet, ikke nærmere specificeret	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
Drug dependence in childbirth	Substance dependence in childbirth
Rusmiddelafhængighed hos moderen, der komplicerer graviditet, fødsel OG/ELLER puerperium	Substance dependence in mother complicating pregnancy, childbirth and/or puerperium (disorder)
stofafhængighed i remission	Substance dependence in remission
Drug dependence, continuous	Substance dependence, continuous
episodisk stofafhængighed	Substance dependence, episodic (disorder)
Drug for supraventricular arrhythmia	Antiarrhythmic agent (substance)
Drug for ventricular arrhythmia	Antiarrhythmic agent (substance)
Drug gel, 0,05%	A semi-solid dose form consisting of a hydrophilic gel.
Drug gel, 0,1%	A semi-solid dose form consisting of a hydrophilic gel.
Drug gel, 0,25%	A semi-solid dose form consisting of a hydrophilic gel.
bivirkning af lægemidler med primær virkning på huden	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på nervesystemet	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på det kardiovaskulære system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på centralnervesystemet	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på det gastrointestinale system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på det muskuloskeletale system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
bivirkning af lægemiddelgrupper med primær effekt på respirationssystemet	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting the autonomic nervous system	Product containing autonomic agent (product)
Drug hypersensitivity (& [NOS])	Propensity to adverse reactions to drug
Drug hypersensitivity	Propensity to adverse reactions to drug
Drug hypersensitivity NOS	Propensity to adverse reactions to drug
Drug induced rash (& ingestion dermatitis)	Dermatitis caused by substance taken via oral route (disorder)
lægemiddelniveau i urinprøve over terapeutisk interval	Urine substance level above reference range (finding)
Drug ointment, 0,025%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,05%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,1%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,2%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,25%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 1%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 2,5%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug reaction - CNS drug	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction to analgesic NOS	Analgesic adverse reaction
Drug reaction to analgesic NOS	Analgesic adverse reaction
lægemiddelspecifikt allergenekstrakt	Pharmaceutical / biologic product (product)
Drug therapy NOS	Drug therapy (procedure)
Drug therapy NOS	Drug therapy (procedure)
status for behandling med lægemiddel	Drug therapy with explicit context
rusmiddelabstinens	Substance withdrawal
anfald ved ophør af indtagelse af afhængighedsskabende stof	Seizure co-occurrent and due to substance withdrawal
Drug withdrawal syndrome	Substance withdrawal
Lægemiddelseponeringssyndrom	Substance withdrawal
Drug, medicament or biological substance	A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.
forhøjede niveauer af lægemidler, medikamenter og biologiske stoffer i urin	Urine substance level above reference range (finding)
medikamentelt fremkaldt impotens	Erectile dysfunction caused by drug
medikamentelt fremkaldt diabetes insipidus nephrogenica	Acquired vasopressin resistance
lægemiddelrelateret sygdom	Disease
Drugs for guinea worms [no drugs here]	Anthelmintic
Drugs for hookworms	Anthelmintic
Drugs for the control of epilepsy	Anticonvulsant
Drugs for threadworms	Anthelmintic
Drugs for trichomonacides	Antiprotozoal
Drugs in urine abnormal [D]	Substance in urine detected by screening method (finding)
lægemidler der anvendes ved hyperurikæmi	Uricosuric agent (substance)
Drugs used in infections	Anti-infective agent (substance)

Start Previous Page 57 of 234 Next End

Reference Sets

Reference set descriptor

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
900000000001156010	REPLACED BY association reference set (foundation metadata concept)	en	Fully specified name	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)
900000000001157018	REPLACED BY association reference set	en	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)